The approved PARP inhibitor niraparib has been beneficial for patients with recurrent ovarian cancer, but new second-line restrictions for certain patients have led physicians to be more cautious when re-challenging these patients.
Treatment With PARP Inhibitors for Patients With Ovarian Cancer
Matthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.
During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the updated results of the PAOLA-1 trial of bevacizumab followed by olaparib maintenance in patients with advanced ovarian cancer. This is the third of 3 articles based on this event.
During a Targeted Oncology™ Case-Based Roundtable™ event, Paul DiSilvestro, MD, discussed the results of the PRIMA trial of niraparib maintenance therapy for patients with advanced ovarian cancer. This is the second of 3 articles based on this event.
During a Targeted Oncology case-based roundtable event, Paul D. DiSilvestro, MD, discussed the long-term results from the SOLO-1 trial of olaparib maintenance for patients with ovarian cancer. This is the first of 3 articles based on this event.
During a live virtual event, Adam C. ElNaggar discussed with participants whether patients who respond to PARP inhibitors for advanced ovarian cancer should continue to receive them indefinitely.
During a live virtual event, Adam C. ElNaggar, MD, discussed with participants their experiences with PARP inhibitors in patients with ovarian cancer.
During a live virtual event, Matthew L. Anderson, MD, PhD, discussed the results of the PRIMA study of niraparib in patients with wild-type and BRCA-mutated ovarian cancer.
During a live virtual event, Matthew L. Anderson, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for treating patients with advanced ovarian cancer using PARP inhibitors based on BRCA mutation status and other factors.